{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044932","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.088598+00:00","generated_at":"2026-05-30T01:07:18.703685+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Calidi Biotherapeutics Q3 net loss widens to $5.1M; FDA clears NeuroNova IND","bullets":["Net loss of $5.1M ($0.65/share) vs. $2.0M ($1.41/share) in Q3 2023.","R&D expenses $2.2M, down from $3.3M; G&A $3.1M, down from $4.0M.","Cash and restricted cash $2.1M as of Sept 30, 2024, unchanged from Dec 31, 2023.","FDA cleared IND for NeuroNova (CLD-101) Phase 1b/2 trial in high-grade glioma; trial expected early 2025.","Raised $2M in registered direct offering and private placement in October."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044932","json":"https://secwatch.observer/filing/0001493152-24-044932.json","markdown":"https://secwatch.observer/filing/0001493152-24-044932.md","text":"https://secwatch.observer/filing/0001493152-24-044932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224044932/0001493152-24-044932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224044932/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:07:18.703685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}